Skip to main content
NCBI home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1982 Aug 14;285(6340):465–467. doi: 10.1136/bmj.285.6340.465

Reduction in size of prolactin-secreting tumours in men treated with pergolide.

P Kendall-Taylor, K Hall, D G Johnston, R W Prescott
PMCID: PMC1499261  PMID: 6809126

Abstract

The effect of pergolide mesylate was studied in two previously untreated men with large prolactinomas and exceptionally high prolactin concentrations. The study was designed to determine whether pergolide would be effective in alleviating symptoms, correcting hormonal abnormalities and shrinking the tumour. Starting with 50 micrograms daily the dose of pergolide was slowly increased over 10 weeks to 1 mg once daily, when repeat assessment was performed. Both patients reported complete relief of symptoms, with no side effects. Serum prolactin concentration was suppressed to normal in both subjects, and evidence to suggest tumour shrinkage was observed. Pergolide appears to be effective treatment for men with large prolactinomas.

Full text

PDF
465

Images in this article

466Case 2
on p.466

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Franks S., Horrocks P. M., Lynch S. S., Butt W. R., London D. R. Treatment of hyperprolactinaemia with pergolide mesylate: acute effects and preliminary evaluation of long-term treatment. Lancet. 1981 Sep 26;2(8248):659–661. doi: 10.1016/s0140-6736(81)90997-1. [DOI] [PubMed] [Google Scholar]
  2. George S. R., Burrow G. N., Zinman B., Ezrin C. Regression of pituitary tumors, a possible effect of bromergocryptine. Am J Med. 1979 Apr;66(4):697–702. doi: 10.1016/0002-9343(79)91187-2. [DOI] [PubMed] [Google Scholar]
  3. Goldstein M., Lieberman A., Lew J. Y., Asano T., Rosenfeld M. R., Makman M. H. Interaction of pergolide with central dopaminergic receptors. Proc Natl Acad Sci U S A. 1980 Jun;77(6):3725–3728. doi: 10.1073/pnas.77.6.3725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Grossman A., Yeo T., Delitala G., Hathway N. R., Besser G. M. Two new dopamine agonists that are long acting in vivo but short acting in vitro. Clin Endocrinol (Oxf) 1980 Dec;13(6):595–599. doi: 10.1111/j.1365-2265.1980.tb03428.x. [DOI] [PubMed] [Google Scholar]
  5. Kleinberg D. L., Lieberman A., Todd J., Greising J., Neophytides A., Kupersmith M. Pergolide mesylate: a potent day-long inhibitor of prolactin in rhesus monkeys and patients with Parkinson's disease. J Clin Endocrinol Metab. 1980 Jul;51(1):152–154. doi: 10.1210/jcem-51-1-152. [DOI] [PubMed] [Google Scholar]
  6. Lemberger L., Crabtree R. E. Pharmacologic effects in man of a potent, long-acting dopamine receptor agonist. Science. 1979 Sep 14;205(4411):1151–1153. doi: 10.1126/science.382359. [DOI] [PubMed] [Google Scholar]
  7. Lemberger L., Crabtree R., Callaghan J. T. Pergolide, a potent long-acting dopamine-receptor agonist. Clin Pharmacol Ther. 1980 May;27(5):642–651. doi: 10.1038/clpt.1980.91. [DOI] [PubMed] [Google Scholar]
  8. McGregor A. M., Scanlon M. F., Hall R., Hall K. Effects of bromocriptine on pituitary tumour size. Br Med J. 1979 Sep 22;2(6192):700–703. doi: 10.1136/bmj.2.6192.700. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Prescott R. W., Johnston D. G., Kendall-Taylor P., Crombie A., Hall K., McGregor A., Hall R. Hyperprolactinaemia in men-response to bromocriptine therapy. Lancet. 1982 Jan 30;1(8266):245–248. doi: 10.1016/s0140-6736(82)90975-8. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES